The Johnson & Johnson (J&J) COVID-19 vaccine will remain on pause after an advisory committee to the Centers for Disease Control and Prevention (CDC) said it needed more data to be able to vote on a recommendation, which may come in a week to 10 days. Federal health officials halted the use of the J&J vaccine after reports of rare and severe blood clots in the brain with reduced blood platelet levels (thrombocytopenia) occurred after some people were inoculated. The Advisory Committee on Immunization Practices (ACIP), tasked with developing recommendations on the use of vaccines, held an emergency meeting Wednesday afternoon to discuss the incidence of blood clots with low platelets in seven people following the J&J vaccine. But data was available for only six of the seven individuals. More than 7.2 million doses of the J&J COVID-19 vaccine have been administered as of April 14. The clotting disorder in …